past issues

past issues

1998  
December
1999

Click Here to Download the Full 1999 Archive
January February March April
May June July August
September October November December
2000

Click Here to Download the Full 2000 Archive
January February March April
May June July August
September October November December
2001

Click Here to Download the Full 2001 Archive
January February March April
May June July August
September October November December
2002

Click Here to Download the Full 2002 Archive
January February March April
May June July August
September October November December
2003  
January February March April
May June July August
September October November December
2004  
January February March April
May June July August
September October November December

Topic Listing

HIGHLIGHTS OF THE 1999 ASCO ANNUAL MEETING 
HIGHLIGHTS OF THE 1999 ASH ANNUAL MEETING
HIGHLIGHTS OF THE 2000 ASCO ANNUAL MEETING 
HIGHLIGHTS OF THE 2000 ASH ANNUAL MEETING 
HIGHLIGHTS OF THE 2001 ASCO ANNUAL MEETING 
HIGHLIGHTS OF THE 2001 ASH ANNUAL MEETING
HIGHLIGHTS OF THE 2002 ASCO ANNUAL MEETING 
HIGHLIGHTS OF THE 2002 ASH ANNUAL MEETING
HIGHLIGHTS OF THE 2003 ASCO ANNUAL MEETING 
HIGHLIGHTS OF THE 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
ACUTE MYELOID LEUKEMIA
Gemtuzumab ozogamicin treatment in children
Mylotarg in first relapse
Nuclear factor (NF)-kB expression
ADOPTIVE IMMUNOTHERAPY
Antileukemic activity of allorestricted cytotoxic T lymphocytes (CTLs)
ALLOGENEIC STEM-CELL TRANSPLANTATION 
Donor lymphocyte infusion (DLI) therapy for relapsed multiple myeloma
Therapy for renal-cell carcinoma
B-CELL LYMPHOMA 
Homodimers of Rituxan  
Idiotype (Id)-pulsed dendritic cell (DC) vaccination 
Pretargeted radioimmunotherapy 
BEVACIZUMAB
Front-line therapy for advanced colorectal cancer (advCRC)
Phase III study of combination therapy with IFL
B-LYMPHOPROLIFERATIVE DISORDER
Anti-interleukin-6 (IL-6) treatment 
BONE MARROW TRANSPLANTATION
Allospecific T-cell depletion
Improved outcome with T-cell depletion
BORTEZOMIB 
Phase II studies in NHL
BREAST CANCER
Anti-HER2 monoclonal antibody (MAb) and geldanamycin (GA) immunoconjugate
Combination docetaxel and trastuzumab therapy
Effects of soluble recombinant human CD40 ligand
Reactivated memory T cells
Recombinant Human Anti-HER2 Monoclonal Antibody
Trastuzumab combined with chemotherapy
Trastuzumab combined with taxanes
Trastuzumab plus chemotherapy in metastatic disease
CANCER VACCINES
Anti-carcinoembryonic antigen (CEA) immune response
CERVICAL CANCER
Human leukocyte antigen class I gene mutations
CETUXIMAB
Metastatic colorectal cancer (MCRC)
CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA
Efficacy of rituximab therapy
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Campath-1H after fludarabine failure
CD20 levels and response to rituximab
CD40 activation of CLL-B-cells
Clinical significance of tumor necrosis factor-a (TNF-a) plasma level
Combination Campath-1H and fludarabine therapy
First-line treatment with Campath-1H
Fludarabine followed by alemtuzumab (Campath-1H)
Fludarabine with concurrent or sequential rituximab
New Rituximab dosing regimens
CHRONIC MYELOGENOUS LEUKEMIA (CML)
Donor lymphocyte infusions and durable remissions
Donor lymphocyte infusion (DLI) administration and GVHD
Effects of interferon-a (IFN) therapy on allogeneic bone marrow transplantation (BMT) outcomes
Effect of pretransplant interferon (IFN) therapy
High-dose imatinib mesylate after failure of interferon
Interferon effects
Leukemia-reactive cytotoxic T lymphocytes
Molecular heterogeneity in cytogenetic responders
Resistance to STI-571
T-cell-depleted (TCD) vs. non-T-cell depleted allogeneic bone marrow transplantation (BMT)
Polyethylene glycol (PEG) interferon (IFN)-a therapy
Response to imatinib mesylate
T-cell depletion combined with donor leukocyte infusion therapy
Treatment with interferon alpha (IFN-a) and low-dose cytarabine (ara-C)
COLON CANCER
Responses to an anti-idiotype monoclonal antibody
Edrecolomab adjuvant therapy does not provide clinical benefit
COLORECTAL CANCER 
Bevacizumab plus fluorouracil (FU)/leucovorin (LV)
CUTANEOUS T CELL LYMPHOMA
Interleukin-12 therapy
CYTOMEGALOVIRUS (CMV) INFECTION
Role of Campath-1H
DENDRITIC CELLS (DCS)
DC derived from acute myelogenous leukemia (AML) cells
Effects of vascular endothelial growth factor (VEGF)
Effects of interleukin-6 and macrophage colony-stimulating factor (M-CSF)
DENDRITIC CELL (DC) FUNCTION AND DEVELOPMENT
Effects of FLT3-ligand (FL) administration
EFFECT OF CANCER ON IMMUNE FUNCTION
Defective function of Langerhans cells (LC)
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITION 
ZD1839 (Iressa)
EPSTEIN-BAR VIRUS-LYMPHOPROLIFERATIVE DISEASE (EBV-LPD)
Preemptive rituximab
FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA (AML) 
Phase II studies of 2 novel agents
GEMTUZUMAB OZOGAMICIN
Association with hepatic venoocclusive disease
GRAFT-VERSUS-HOST DISEASE (GVHD)
Anti-CD147 therapy
CD6+ donor marrow T-cell depletion (TCD)
Effect of adding Campath-1G to the conditioning regimen
Granulocyte-colony stimulating factor (G-CSF) mobilization of dendritic cells (DCs)
Immune reconstitution
Monoclonal antibody (MoAb) therapy
Monoclonal antibody (mAb) treatment in a murine model
Treatment with daclizumab
Use of CD52 monoclonal antibodies (MoAbs) to prevent GVHD
Visilizumab treatment of steroid-refractory acute GVHD
GRAFT VS. TUMOR INDUCTION
Donor leukocyte infusion (May 1999), (June 1999) 
HAIRY CELL LEUKEMIA
Efficacy of the anti-CD22 recombinant immunotoxin BL22
HEMATOLOGIC MALIGNANCIES
Immune recognition of myeloma cells
In vivo CAMPATH-1H for graft-versus-host disease (GVHD) prevention
HEPATOCELLULAR CARCINOMA
Adoptive immunotherapy
Escape from immune surveillance
Incidence of chronic hepatitis C virus
Interferon therapy and chronic HCV patients: reduced risk
HER-2/NEU GENE
Anti-HER-2/neu treatments
Immune Antitumor Response
HER2-TARGETED THERAPY
Cardiac safety of trastuzumab (T)
Phase I study of pertuzumab
HODGKIN'S DISEASE 
Bispecific molecule (H22xKi-4)
IDIOPATHIC THROMBOCYTOPENIA (ITP)
Effect of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF)
IMATINIB MESYLATE
Molecular targeting of platelet-derived growth factor B (PDGFB)
INHIBITORS OF EGFR 
GW572016
INTERFERON ALFA THERAPY
Colon carcinoma
Chronic myelogenous leukemia (CML)
INTERLEUKIN 2
Direct gene transfer
LEUKEMIA
Adoptive immunotherapy to prevent relapse of acute leukemia
Cytotoxic T lymphocytes (CTL) specific for the Wilm’s tumor gene encoded transcription factor (WT1)
CD38 ligation
Gemtuzumab zogamicin
131I-anti-CD45 antibody in acute leukemia
Immune gene therapy for chronic lymphocytic leukemia
Immunostimulation of chronic lymphocytic leukemia (CLL) B cells
Immunotherapy with ex vivo-generated cytotoxic T lymphocytes
Inhibition of Bcr-Abl tyrosine kinase
Mechanisms of resistance to the tyrosine kinase inhibitor STI571
Persistence of BCR-ABL rearrangement in chronic myeloid leukemia
Priming with granulocyte colony-stimulating factor (G-CSF) in acute myeloid leukemia (AML)
Rituximab treatment of relapsed patients with hairy cell leukemia (HCL)
T-cell depletion of bone marrow transplants
Treatment of relapsed leukemia with unrelated donor leukocyte infusions
LOW-GRADE NON-HODGKIN'S LYMPHOMA (NHL)
Treatment with anti-CD20 monoclonal antibody and CHOP chemotherapy
LUNG CANCER
NY-ESO-1 expression
LYMPHOID MALIGNANCIES 
Alemtuzumab plus rituximab
First-line and maintenance rituximab treatment
Mechanisms of rituximab resistance
MALIGNANT GLIOMA
Iodine-131-labeled 81C6 monoclonal antibody (mAb) therapy
Nonablative allogeneic hematopoietic transplantation
Retroviral delivery of interleukin-4
MALIGNANT LYMPHOMA 
Rituximab for central nervous system (CNS) lymphomas
Rituximab for relapsed Hodgkin's disease
MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Intrapleural administration of interleukin-2 (IL-2)
MANTLE CELL LYMPHOMA
Graft vs. lymphoma
Induction therapy with rituximab plus CHOP
METASTATIC BREAST CANCER
Trastuzumab and vinorelbine as first-line therapy
METASTATIC MELANOMA
Adjuvant interferon alfa-2b
Autologous Melanoma Vaccine
Combination chemoimmunotherapy
Combination of chemotherapy with interleukin-2 (IL-2) and interferon alfa (IFNa)
Phase I study of a chimeric monoclonal antibody
MULTIPLE MYELOMA (MM)
Bortezomib therapy of relapsed and refractory MM
Cytokine-based tumor cell vaccine
Dendritic cells (DC)
Effects of aminobisphosphonates on T cells
Idiotype (Id)-specific cytotoxic T lymphocytes
Idiotype vaccination
Immunomodulatory drugs
Interferon and Multiple Myeloma
Meta-analysis of interferon (IFN) trials
Muc-1 core protein expression
Novel agents
Nuclear factor (NF)-kB blockade
Thalidomide alone or with dexamethasone
Thalidomide and doxorubicin and deep venous thrombosis (DVT)
Therapy with attenuated measles virus
Vaccination Therapy 
Vascular endothelial growth factor (VEGF) effects
MYELODYSPLASTIC SYNDROME
CC-5013 treatment of MDS-associated anemia
Thalidomide therapy
MYELOFIBROSIS WITH MYELOID METAPLASIA (MMM)
Combination thalidomide plus prednisone therapy
MYELOID LEUKEMIA
Targeted a particle radioimmunotherapy
MYLOTARG
Hepatic toxicity 
NEUROBLASTOMA
Anti-GD2 monoclonal antibody therapy
NEW BIOLOGICAL APPROACHES
New monoclonal antibody therapies
Novel strategies
NON-HODGKIN'S LYMPHOMA (NHL)
Astatine-211 (211At)-labeled rituximab (chimeric anti-CD20 monoclonal antibody)
Bispecific antibody (BsAb) therapy
CHOP followed by tositumomab/iodine-131 tositumomab
CHOP plus rituximab vs. CHOP alone
Clearing of bcl-2-positive cells with rituximab therapy
Down-regulation of Bcl-2 by rituximab
First line rituximab (anti-CD20 monoclonal antibody therapy)
First-line therapy of low-grade NHL with rituximab
Ibritumomab tiuxetan radioimmunotherapy
Interferon alfa consolidation
In vitro biologic response to rituximab
In vivo purging with chemotherapy and rituximab
Iodine-131-tositumomab multimodal therapy
Long-term follow-up after radioimmunotherapy
Molecular profiling
Negative adjuvant therapy trial with anti-B4-blocked ricin (Anti-B4-bR) immunotoxin
Oral CD40 ligand (CD40L) gene therapy
Phase I/II trial of epratuzumab
Pivotal trial of Iodine I 131 tositumomab
Posttransplant lymphoproliferative disorders
Radioimmunotherapy (RIT) with IDEC-Y2B8
Response criteria
Rituximab (an anti-CD20 MoAb) pharmacokinetics
Rituximab in combination with CHOP
Rituximab retreatment
Rituximab treatment: a European experience
Safety profile of Zevalin®
Use of dendritic cells (DCs) to induce idiotype-specific CTLs
Vaccine induced molecular remission
NON-SMALL CELL LUNG CARCINOMA (NSCLC)
Gefitinib therapy of recurrent or refractory NSCLC
OVARIAN CANCER
Phototherapy and cisplatin
p53 TUMOR SUPPRESSION FUNCTION
Effect on anti-angiogenesis therapy
PALLIATION OF TRANSPLANTATION COMPLICATIONS
Anti-B-cell antibody therapy of B-lymphoproliferative disorder (PTBCL)
PANCREATIC CANCER
Phase I trial of a tumor vaccine
Phase II study of the farnesyltransferase inhibitor R115777

Phase I and II Studies
Phase I study of cantuzumab mertansine
Phase II study of trastuzumab in gynecologic tumors

Phase I Studies of New Therapies
Cancer vaccine
Farnesyl transferase inhibitor
Oncolytic virus
PHASE I STUDY RESULTS
Novel agents
PLASMA CELL DYSCRASIA
Treatment with thalidomide
POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE (PTLD)
Effectiveness of partly HLA-matched allogeneic cytotoxic lymphocytes (CTLs)
PRECLINICAL STUDIES
Fc receptor modulation of antibody cytotoxicity
PROSTATE CANCER
Antigen-loaded dendritic cells
Antigen-specific cellular immunity
Bispecific antibody therapy
PROTEASOME INHIBITOR
Molecular mechanisms of activity
Radioimmunotherapy (RIT)
90Y ibritumomab tiuxetan vs. rituximab
Iodine-131-tagged anti-CD30 antibody treatment of refractory Hodgkin's lymphoma (HL)
131I tositumomab treatment of mantle cell lymphoma (MCL)
I 131-tositumomab treatment of previously untreated advanced FL
Y90-Zevalin treatment of relapsed low grade and follicular non-Hodgkin's lymphoma (NHL)
90y-ibritumomab for relapsed B-cell NHL following high-dose chemotherapy and ASCT
RECOMBINANT HUMANIZED MONOCLONAL ANTIBODY TO VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
Phase I studies
RELAPSED CHRONIC MYELOGENOUS LEUKEMIA (CML)
Donor lymphocyte infusion (DLI)
RENAL CELL CARCINOMA
Adjuvant interferon alfa therapy
Graft vs. tumor effects: a case report
Cytokine therapy
Identification of a potential immunotherapy target
Pegylated interferon alfa-2a
Tumor infiltrating lymphocytes plus recombinant IL-2

RITUXIMAB
Acquired factor VIII inhibitors
Combined with CHOP for HIV-associated non-Hodgkin's lymphoma (NHL)
Concurrent versus sequential treatment with FND chemotherapy (fludarabine, mitoxantrone, dexamethasone)
Combination with hyper-CVAD in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma
Complement-dependent cytotoxicity (CDC)
Indolent non-Hodgkin's lymphoma (NHL)
In combination with CHOP (R-CHOP)
Prolonged Rituximab treatment
Synergy with glucocorticoids (GCs)
Treatment of fludarabine-associated immune thrombocytopenia (ITP)
RITUXIMAB-REFRACTORY FOLLICULAR NON-HODGKIN'S LYMPHOMA (NHL)
Radioimmunotherapy with ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals)
RITUXIMAB THERAPY (ANTI-CD20 CHIMERIC ANTIBODY)
Effects on B-cell chronic lymphocytic leukemia (CLL)
Efficacy in bulky NHL
Cytokine release syndrome
Infusion-related side effects
Mechanism of action via generation of superoxide radicals
Mechanism of action
Minimal residual disease (MRD) after CHOP and rituximab
Treatment of pure red blood cell aplasia (PRCA) in 2 CLL patients
RITUXIMAB WITH CHEMOTHERAPY AND AS A SINGLE AGENT
Rituximab-CHOP (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL)
R-CHOP for follicular lymphoma
R-CVP in follicular lymphoma
Rituximab (R) plus fludarabine combination therapy of untreated chronic lymphocytic leukemia (CLL)
Maintenance therapy vs. retreatment with rituximab (R) for patients with indolent non-Hodgkin's lymphoma (NHL)
T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PILL)
High remission rate with CAMPATH-1H
THERAPY FOR RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA (NHL)
Extended rituximab therapy
Rituximab (a chimeric anti-CD20 monoclonal antibody) therapy)
Myeloablative 131 l-anti-CD20 antibody therapy
131 l- LYM-1 dose finding study 
CAMPATH-1H (a human anti-CD52 monoclonal antibody) therapy
Radioimmunoconjugate therapy
TRANSPLANTATION
Effects of 131 l-anti-CD45 antibody in murine transplant models
HLA-mismatched hematopoietic stem cell transplantation
TUMOR ANTIGEN IDENTIFICATION
TRASTUZUMAB 
First-line therapy for metastatic breast cancer
In combination with ZD1839
Lethality-based selection of recombinant genes 
TUMOR CELL VACCINATION
Cellular immune response mechanisms
Enhancement of graft-versus-tumor (GVT) activity
TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) 
Preclinical studies
TUMOR-SPECIFIC ANTIGENS
Human myeloma cells
TYROSINE KINASE INHIBITION
STI571 early clinical trials
VACCINE THERAPY
Anti-idiotype vaccine for melanoma
Chronic myelogenous leukemia
muc1 tumor antigen
Renal cell carcinoma
Use in patients with mantle-cell lymphoma (MCL)
Waldenstrom’s Macroglobulinemia (WM)
Rituximab treatment